COVID-19 Vaccine Information

This page last updated: 01/25/2022 12:30

  • Moderna vaccine quantity on hand: > 500

  • Pfizer vaccine (ages 5 to 11) quantity on hand: 50

  • Pfizer vaccine (ages 12 to 17) quantity on hand: 280

  • Influenza vaccine quantity on hand: 9

 

 

PLEASE READ THE FOLLOWING INFORMATION CAREFULLY.

We are expecting a large shipment of rapid at-home COVID-19 antigen tests to arrive soon, depending on wholesaler supply. Test inventory will be added above when they become available.

Riverside Remedies has been selected by the Department of Health and Human Services to provide oral antiviral medications for the treatment of mild-to-moderate COVID-19.
Scroll to the end of this page for details.

For all vaccine recipients: please have your vaccine card and consent form ready upon arrival to minimize delay.

 

When can I receive my vaccine?

Vaccine administration is offered weekly, Monday through Thursday, between 10:00 am and 5:00 pm, or until supplies run out.

We are typically able to restock supply within one week of running out; the expected ETA for the next shipment will be shown at the top of this page once the order has been approved by the NYS Department of Health.

No appointment is necessary, though we recommend arriving as early as possible.

Individuals arriving later in the afternoon or evening may be asked to return at a different time or on another day to minimize the risk of discarding unused doses.

Out-of-state residents may be vaccinated by New York providers, however you must still complete the online NYS COVID-19 Vaccination Form for the NYS Department of Health.

 

Regarding heterologous (i.e. “mix-and-match”) dosing:

The FDA discontinued the requirement that booster doses must be from the same manufacturer as the primary series, primarily as a measure to increase vaccination rates among eligible individuals by not limiting providers based on the type of vaccine available at any given time.

Individuals may receive either of the two mRNA vaccines (Pfizer or Moderna) as a booster dose.

An added benefit of heterologous boosting is that immunity appears to be superior and more durable than receiving three doses of the same vaccine. This is particularly important for individuals who have received the Pfizer vaccine, as efficacy wanes considerably with time and age. However, individuals who have received two doses of the Moderna vaccine are probably less likely to benefit from a third dose of the Pfizer vaccine as opposed to a third dose of the Moderna vaccine. We recommend that all eligible individuals receive a third dose of the Moderna vaccine.

Note that heterologous dosing only applies to booster doses at this time. Both primary course doses must still be identical, as well as third-dose revaccinations.

 

Now that you will have both mRNA vaccines in stock and available for adults, can I choose which one I get?

No; our Pfizer stock will be quite limited and used preferentially for those under 18.

All primary series vaccinations and booster doses for adults will be Moderna only.

 

Regarding vaccine dose amounts:

For the Moderna vaccine (ages 18 and up):

  • Primary series: two 0.5 mL doses, separated by 28 days.
  • Third-dose revaccination for immunocompromised individuals: one 0.5 mL dose at least one month after completing the primary series.
  • Booster dose: one 0.25 mL dose at least six months after completing the primary series.

For the pediatric Pfizer vaccine (ages 5 to 11) :

  • Primary series: two 0.2 mL doses, separated by 21 days.
  • Third-dose revaccination for immunocompromised individuals: one 0.2 mL dose at least one month after completing the primary series.
  • Booster dose: not currently authorized or recommended by the FDA and CDC.

For the adolescent/adult Pfizer vaccine (ages 12 and up):

  • Primary series: two 0.3 mL doses, separated by 21 days.
  • Third-dose revaccination for immunocompromised individuals: one 0.3 mL dose at least one month after completing the primary series.
  • Booster dose: one 0.3 mL dose at least five months after completing the primary series.

 

Regarding Moderna vaccine eligibility:

There are three classes of Moderna vaccine eligibility, as outlined below. The dose you receive, and when you can receive it, depends on whether the immunization is a third-dose revaccination or a third-dose booster.

  • Primary series (full dose, 100 μg/0.5 mL): available to any individual aged 18 or older.
  • Third dose (full dose, 100 μg/0.5 mL) for severely immunocompromised individuals:
    • Given at least 28 days after completion of the primary series.
    • Administered due to a medical condition or receipt of immunosuppressive medications or treatments which may have impaired response to the primary series. These conditions and treatments include but are not limited to:
      • Active treatment for solid tumor and hematologic malignancies,
      • Receipt of solid-organ transplant and taking immunosuppressive therapy,
      • Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy),
      • Moderate or severe primary immunodeficiency,
      • Advanced or untreated HIV infection,
      • Active treatment with high-dose corticosteroids (e.g. > 20 mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-associated immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory.
  • Booster dose (half dose, 50 μg/0.25 mL) for the following individuals:
    • Available to the following recipients:
      • All individuals aged 18 or older.
    • Timing after previous doses…
      • At least six months after the second dose for past recipients of Moderna or Pfizer vaccines, OR
      • At least two months after a single dose of the Janssen vaccine.

Regarding Pfizer vaccine eligibility:

Like the Moderna vaccine, there are three classes of Moderna vaccine eligibility. The dose you receive, and when you can receive it, depends on the recipient’s age and whether the immunization is a third-dose revaccination or a third-dose booster.

Adult/adolescent Pfizer vaccine (a.k.a. Comirnaty):

  • Primary series (full dose, 30 μg/0.3 mL): available to any individual aged 12 or older. Two doses separated by 21 days.
  • Third dose (full dose, 30 μg/0.3 mL) for severely immunocompromised individuals:
    • Given at least 28 days after completion of the primary series.
    • Administered due to a medical condition or receipt of immunosuppressive medications or treatments which may have impaired response to the primary series. These conditions and treatments include but are not limited to:
      • Active treatment for solid tumor and hematologic malignancies,
      • Receipt of solid-organ transplant and taking immunosuppressive therapy,
      • Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy),
      • Moderate or severe primary immunodeficiency,
      • Advanced or untreated HIV infection,
      • Active treatment with high-dose corticosteroids (e.g. > 20 mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-associated immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory.
  • Booster dose (full dose, 30 μg/0.3 mL) for the following individuals:
    • Available to the following recipients:
      • All individuals aged 12 or older.
    • Timing after previous doses…
      • At least six months after completing a Moderna primary course, OR
      • At least five months after completing a Pfizer primary course, OR
      • At least two months after a single dose of the Janssen vaccine.

Pediatric Pfizer vaccine (not Comirnaty):

  • Primary series (full dose, 10 μg/0.2 mL): available to any individual aged 5 to 11. Two doses separated by 21 days.
    If a child turns from 11 to 12 years of age between their first and second doses of the primary series, they may receive either strength.
  • Third dose (full dose, 10 μg/0.2 mL) for severely immunocompromised individuals:
    • Given at least 28 days after completion of the primary series.
    • Administered due to a medical condition or receipt of immunosuppressive medications or treatments which may have impaired response to the primary series. These conditions and treatments include but are not limited to:
      • Active treatment for solid tumor and hematologic malignancies,
      • Receipt of solid-organ transplant and taking immunosuppressive therapy,
      • Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy),
      • Moderate or severe primary immunodeficiency,
      • Advanced or untreated HIV infection,
      • Active treatment with high-dose corticosteroids (e.g. > 20 mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-associated immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory.
  • Booster dose (full dose, 10 μg/0.2 mL) for the following individuals:
    • Not currently recommended or approved by the FDA and CDC.

Consent forms and procedure:

For unvaccinated children aged 5 to 11 seeking their first dose of the pediatric Pfizer vaccine:

  • Verify eligibility:
    • Currently any child, aged 5 to 11 years of age, may receive the pediatric 10 μg Pfizer vaccine with parental consent.
  • Print and complete the COVID-19 Vaccine Consent Form.
  • Complete the online NYS COVID-19 Vaccination Form prior to arriving at the pharmacy.
  • Arrive at the pharmacy between 10:00 am and 5:00 pm, Monday through Thursday, with the completed consent form.
  • The second appointment will be scheduled for 21 days after the date of the first vaccination. Due to the sensitive storage requirements for the Pfizer vaccine, you must return to the original provider to receive the second dose. Please make all efforts to adhere to the 21 day timing interval.

 

For unvaccinated children aged 12 to 17 seeking their first dose of the adult Pfizer vaccine (coming soon):

  • Verify eligibility:
    • Currently any child, aged 12 to 17 years of age, may receive the adult 30 μg Pfizer vaccine with parental consent.
  • Print and complete the COVID-19 Vaccine Consent Form.
  • Complete the online NYS COVID-19 Vaccination Form prior to arriving at the pharmacy.
  • Arrive at the pharmacy between 10:00 am and 5:00 pm, Monday through Thursday, with the completed consent form.
  • The second appointment will be scheduled for 21 days after the date of the first vaccination. Due to the sensitive storage requirements for the Pfizer vaccine, you must return to the original provider to receive the second dose. Please make all efforts to adhere to the 21 day timing interval.

 

For unvaccinated adults seeking their first or second dose (primary course) of the Moderna vaccine:

  • Verify eligibility:
    • Currently any individual 18 or older may receive the Moderna vaccine.
  • Print and complete the COVID-19 Vaccine Consent Form.
  • Complete the online NYS COVID-19 Vaccination Form prior to arriving at the pharmacy.
  • Arrive at the pharmacy between 10:00 am and 5:00 pm, Monday through Thursday, with your completed consent form and driver’s license.
  • Your second appointment will be scheduled for 28 days after the date of your first vaccination.

 

For adults seeking their first, second, or booster dose of the Pfizer or Janssen vaccines:

  • Change your mind and just get the Moderna vaccine.

 

For immunocompromised adults seeking a third dose (0.5 mL) of the Moderna vaccine:

  • Verify eligibility:
    • The individual previously received two doses of the Moderna vaccine, AND
    • More than 28 days has elapsed since receipt of the most recent Moderna dose, AND
    • The individual meets the eligibility criteria for severe immunocompromisation as described above.
  • Locate your vaccine card to bring to the pharmacy.
  • Print and complete the COVID-19 Vaccine Consent Form.
  • Print and complete the Third-Dose Eligibility Attestation Form.
  • Complete the online NYS COVID-19 Vaccination Form prior to arriving at the pharmacy.
  • Arrive at the pharmacy between 10:00 am and 5:00 pm, Monday through Thursday, with your completed consent form, eligibility attestation form, and vaccine card.

 

For non-immunocompromised adults and adolescents seeking a booster dose:

  • Verify eligibility:
    • The individual previously completed a primary vaccination series for any COVID-19 vaccine, AND
    • Sufficient time has elapsed since receipt of the most recent COVID-19 dose…
      • Janssen: at least two months
      • Pfizer: at least five months
      • Moderna: at least six months, AND
    • The individual is 12 years of age or older.
  • Locate your vaccine card to bring to the pharmacy.
  • Print and complete the COVID-19 Vaccine Consent Form.
  • Complete the online NYS COVID-19 Vaccination Form prior to arriving at the pharmacy.
  • Arrive at the pharmacy between 10:00 am and 5:00 pm, Monday through Thursday, with your completed consent form, eligibility attestation form, and vaccine card.

 

Can I receive a flu shot at the same time as my COVID vaccine?

Yes, flu shots are available for all individuals aged 5 and up.

If you are seeking to have a flu shot administered at the same time as your COVID-19 vaccine, please print and complete the Influenza Vaccine Consent Form ahead of your visit to save time.

We will only be administering standard-dose preservative-free quadrivalent flu vaccines this year. The senior (65+) high-dose and adjuvanted vaccines are 6 to 7 times more expensive than standard-dose vaccines for us to acquire; we decided to maximize the number of individuals we could vaccinate by purchasing only standard-dose vaccines.  (And since we should all continue to be vigilant and proactive in reducing our exposure to communicable diseases by continuing to wear masks and practice social distancing anyway, the marginal benefit of the high-dose and adjuvanted influenza vaccines is perhaps less significant this year.)

Most insurance plans cover flu shots in full; the out-of-pocket cost if not covered or uninsured is $20.00.

 

COVID-19 ORAL ANTIVIRAL THERAPEUTICS

This section will be updated frequently as more details become available. Check back soon for more.

The U.S. Department of Health and Human Services selected Riverside Remedies to provide oral antiviral medications for the treatment of mild-to-moderate COVID-19.

We were informed that the number of providers selected to participate is relatively limited, though we have no other indication at this time as to how many other local providers will also be offered these medications. All providers with antiviral stock are required to report daily inventory to a centralized database, so that prescribers will be able to find local stock quickly.

What medications will be available?

Currently, two oral medications are pending approval by the FDA and CDC to treat mild-to-moderate COVID-19:

  • Paxlovid: a combination drug consisting of:
    • Nirmatrelvir, a novel SARS-CoV-2 protease inhibitor that inhibits viral replication, and
    • Ritonavir, another antiviral not useful against SARS-CoV-2 itself but instead prevents the body from metabolizing the nirmatrelvir too quickly.
  •  Molnupiravir: a single-entity nucleoside analog that prevents SARS-CoV-2 replication by mutagenesis.

We do not currently have either medication on hand at this time. An inventory count will be added to the top of this page once we do begin to receive them.

How are the medications used?

Importantly, these medications can only be used for post-exposure treatment – they cannot be used for pre- or post-exposure prophylaxis for the prevention of COVID-19, nor as a substitute for vaccination.

They also cannot be used for severe disease that require hospitalization, in which case a patient would likely be administered a monoclonal antibody infusion (among other things).

These drugs are only intended to aid the patient in recovering at home from a mild-to-moderate infection, and to possibly help preventing a less serious case from progressing to a more serious one that may require hospitalization. They are analogous to Tamiflu in this way – they won’t prevent you from getting sick in the first place, but once confirmed may help you recover a little more quickly and comfortably.

How do I get an oral antiviral medication if I need one?

We are unsure of all the details at this time, but both drugs will likely require a prescription from a primary care/urgent care/emergency department clinician.

More guidance from the CDC on this point is still forthcoming.

Furthermore – Paxlovid in particular will have a very long list of potential drug interactions, as ritonavir is a potent inhibitor of multiple liver enzyme pathways that metabolize many other common prescription and OTC medications. Proper interaction screening will be critically important, and (pending further regulatory guidance on this matter) we may ask for a detailed list of your current medications prior to dispensing.